Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00643669 · ClinicalTrials.gov registry record · Phase 2
24 Hour IOP Lowering Efficacy of AL-3789
A Phase 2 study, sponsored by Alcon Research.
- Completed
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
NCT00643669 is a Phase 2 study that has completed, run by Alcon Research. The registered enrollment target is 25 participants.
The verdict
NCT00643669, a Phase 2 study, has completed, sponsored by Alcon Research.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
Study Summary
The objective of this study was to describe the intraocular pressure-lowering efficacy of AL-3789 over a 24-hour period in patients with open-angle glaucoma compared to an untreated control. Patients received one treatment of AL-3789. Twenty-eight days after treatment, IOP was measured every 4 hours, beginning at 8 AM for 24 hours.
Interventions
- DRUG AL-3789 Sterile Suspension
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2008-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00643669
The ClinicalTrials.gov registry entry for NCT00643669 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alcon Research, which has 275 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which AL-3789 Sterile Suspension is the first listed.
NCT00643669 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00643669 about?
NCT00643669 is a clinical study titled "24 Hour IOP Lowering Efficacy of AL-3789". The objective of this study was to describe the intraocular pressure-lowering efficacy of AL-3789 over a 24-hour period in patients with open-angle glaucoma compared to an untreated control. Patients received one treatment of AL-3789. Twenty-eight days after treatment, IOP was measured every 4 hours...
What is the current status of trial NCT00643669?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2008-02.
What interventions are being tested in trial NCT00643669?
The interventions under investigation include: AL-3789 Sterile Suspension (DRUG).
Who is sponsoring clinical trial NCT00643669?
This trial is sponsored by Alcon Research, which has 275 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.